In her new function, Visconti is liable for the creative agency’s marketing and advertising intelligence companies as effectively as the groups that contribute to maximizing customer determination-creating and “optimizing the effect of shopper advertising strategies.”
Visconti is a digital marketing and advertising and analytics veteran, owning worked in the discipline given that 2007. She has previously held roles at BioteMedical, a bioidentical hormone alternative therapies provider, as nicely as Belo + Firm, a shopper agency. She also at this time serves as a professor of electronic advertising and analytics at Southern Methodist College.
“Rebecca brings a wealth of specialized and analytical experience to her leadership function at AbelsonTaylor, which is definitely essential in developing powerful advertising strategies in today’s knowledge-intensive planet,” Christopher Dimmock, AbelsonTaylor’s SVP of built-in method, claimed in a assertion. “But she also delivers strong promoting, crew-developing, and collaboration skills and the capacity to use truth-based info to generate measurable company success.”
For her portion, Visconti reported she is thrilled to be functioning with AbelsonTaylor’s team of facts architects and info visualization authorities to progress the organization’s mission forward.
“This is an thrilling time to be in healthcare promoting and I’m happy to be component of the revolutionary operate remaining completed at AbelsonTaylor,” she stated in a statement.
Visconti’s appointment is the most up-to-date in a collection of personnel moves that the 2022 MM+M Company 100 honoree has made this year.
In July, AbelsonTaylor promoted Amy Restko, who has been with the enterprise since 2016, to account setting up director.
In the course of the spring, the company also declared the employ of Jeremy Vannatta as VP, account director. In this function, Vannatta oversees AbelsonTaylor’s oncology customers and experiences to EVP and director of customer services Lynnette Hunter.
The company has been on a steady trajectory amid significant business-broad disruptions similar to the COVID-19 pandemic.
In 2021, revenue rose 13%, to $64.8 million, up from $57.2 million in 2020. Meanwhile, the agency secured assignments from Coherus BioSciences, Arcutis Biotherapeutics, Cooper-Surgical and Aerovate Therapeutics.